BUP-450 for Smoking Cessation

"Based on the available data, bupropion hydrochloride extended release was rated a 2 for safety. This is because it has been tested in previous clinical trials which provide evidence of its security profile but no proof that it can be effective therapeutically."

"This trial is searching for 300 individuals who suffer from anhedonia, aged between 21 and 65. Crucially, candidates must have been smoking at least 10 cigarettes daily for more than 2 years and their breath CO ppm needs to be above 10ppm upon entering the study."

"This medical trial is seeking participants who are of legal age (21+) and under the upper limit of 65 years old."

"Bupropion hydrochloride extended release is primarily used for the treatment of seasonal affective disorder, however it may also be beneficial in managing smoking cessation and related diseases."

"Unfortunately, this clinical trial is no longer accepting applicants. Its announcement was originally made on June 1st 2020 and it has been since updated as of May 18th 2020. On the other hand, there are 212 trials that are still recruiting participants for anhedonia and 31 studies searching for volunteers to participate in research with Bupropion hydrochloride extended release treatments."

"Presently, there are 31 clinical trials being conducted in regards to Bupropion hydrochloride extended release. Of these studies, 10 of them are at the Phase 3 level and 283 different medical centres across the globe have been running tests for this treatment, with a majority situated in New Haven, Connecticut."

"Unfortunately, this clinical trial has already ended its recruitment phase. Initially posted on June 1st 2020 and most recently updated on May 18th 2020, it is no longer open for participation. If you are searching for other studies related to anhedonia, there are currently 212 trials that accept patients; 31 of them involve Bupropion hydrochloride extended release."